IRIC opens new labs, begins Phase II clinical trials

The Institute for Research in Immunology and Cancer (IRIC) has opened new laboratories for its medicinal core facility that will increase drug discovery capacity and accelerate the expansion of its chemical compounds library with the installation of a robotics suite. Located at the Univ of Montreal, IRIC’s new labs are a partnership with the university’s Faculty of Pharmacy and coincide with the launch of Phase II clinical trials for a molecule jointly identified by IRIC and Bristol-Myers Squibb. The drug candidate is being studied for the treatment of thrombotic diseases to inhibit the protease-activated receptor type 4. Several hospitals across Canada and internationally will participate in the trial.